MIR4435-2HG interacts with STAT1 to transcriptionally activate the key glutaminase enzyme GLS1, positioning GLS1 as a potential therapeutic target for FH-deficient RCC [110]. This evidence concerns the gene GLS and renal cell carcinoma.